What Changed in the 2026 Cholesterol Guidelines (And Why It Matters For You)
In March 2026, the American College of Cardiology and American Heart Association released new dyslipidemia guidelines — the first major update in eight years. Three things changed in ways that affect what your doctor recommends. Here's the plainspoken version of what's new and what it means.
What's new at a glance
- LDL targets are lower. Under 70 mg/dL is the new goal for intermediate-risk people; under 55 for high-risk.
- Lp(a) testing is now universal. The guidelines recommend everyone get tested at least once, regardless of other risk factors.
- Statin consideration now starts at age 30. For people with elevated risk, treatment can begin earlier than the old 40-year-old threshold.
Underneath those three headlines, several smaller updates: broader use of apoB, more attention to residual risk after statin therapy, more nuance about young women and pregnancy planning, and acknowledgment of new Lp(a)-lowering drugs in late-stage trials.
The overall direction: start earlier, treat to lower targets, test more thoroughly. The reasoning is that cardiovascular disease is built over decades, and early action compounds.
Why the targets keep dropping
Cholesterol targets have moved lower for 30 years. In the early 1990s, LDL under 130 was considered good. By the 2010s, under 100 became standard. Now, for many people, under 70 is the goal.
The reasoning is consistent and supported by progressively stronger evidence:
- Cardiovascular disease risk drops linearly as LDL drops, with no apparent floor
- Mendelian randomization studies (using genetics to test causation) confirm that lifelong lower LDL prevents heart attacks
- Trials of aggressive LDL lowering (PCSK9 inhibitors, very-low-LDL groups) consistently show fewer cardiovascular events with no safety concerns at very low LDL levels
- The longer someone is at lower LDL, the better — early treatment has compounding benefits
The guidelines are catching up to the evidence. The pace of catch-up depends on accumulated clinical trial data, which moves slowly.
What this means if you're 30
Old guidelines: statins were rarely recommended before age 40 unless you had familial hypercholesterolemia or established heart disease.
New guidelines: statin consideration now starts at 30 for people with:
- LDL above 160 mg/dL with one or more additional risk factors
- Strong family history of early heart disease
- High Lp(a)
- Diabetes or prediabetes
- Calculated 10-year cardiovascular risk above 7.5%
The headlines that ran "Statins now recommended starting at 30" are a simplification. Most healthy 30-year-olds still don't qualify. What changed is that doctors now have explicit guideline support to start earlier when there's a real reason.
For young adults with high cholesterol and family history, this is meaningful. Decades of accumulated cardiovascular damage can be prevented by starting medication 10 years earlier than the old standard. More on the age-30 statin question.
What this means if you're 40
The biggest change for 40-somethings is the lower LDL target. If your previous "good enough" was under 100, the new threshold for intermediate-risk patients is under 70.
Many people with LDL in the 90–110 range will now be encouraged to try lifestyle changes more aggressively, or to add medication, when previously their numbers were considered acceptable. Whether this applies to you depends on your full risk profile, especially Lp(a) and family history.
The Lp(a) testing recommendation matters most in this age group because there's still time to act on the result. Universal testing in 40-year-olds will identify a meaningful number of people whose risk profile is worse than their LDL alone suggests.
What this means if you're 50–60
For most people in this age group, the new guidelines mean continuing what you're doing — perhaps with tighter LDL targets, more aggressive treatment of any modifiable risk factors, and Lp(a) testing if you've never been tested.
If you're already on a statin and your LDL is 80, the new guidelines may push toward adding ezetimibe or considering a higher-intensity statin to get into the under-70 range. This is a conversation with your doctor — not every 80 needs to become 70.
Coronary artery calcium (CAC) scoring is increasingly used to refine risk in this age group. If your risk score is borderline, a CAC scan can tell you whether plaque is already present and adjust treatment intensity accordingly.
What this means if you're 60+
The age-30 conversation barely applies. The big changes for older adults:
- Continued statin use. The 2026 guidelines reaffirm that older adults benefit from statins, push back against the "I'm too old to start" argument.
- Aggressive secondary prevention. If you've had a heart attack or stroke, the new target is under 55 mg/dL, often under 40 with combination therapy.
- Lp(a) once. If you've never been tested, now is fine — the result still matters for managing the rest of your risk.
- More attention to medication tolerance. Recognition that older adults sometimes need lower statin doses or alternative non-statin therapies (ezetimibe, bempedoic acid) due to side effects.
The universal Lp(a) recommendation
Of all the changes, this one is the most actionable for most people. Lp(a) is an inherited cholesterol particle that affects 1 in 5 people, can't be lowered by lifestyle, and changes how aggressively your other risk factors should be managed.
The 2026 guidelines made one-time Lp(a) testing a Class I recommendation. That's the strongest endorsement these guidelines give. Insurance is increasingly covering it. Out of pocket is $20–70.
If you've been seeing your doctor for years and nobody has tested your Lp(a), you're not alone — but now is the time to ask.
What the guidelines don't say (and what's controversial)
A few things worth knowing about the limits of the 2026 guidelines:
They don't endorse aggressive optimization
If you've heard Peter Attia argue for apoB under 60 for everyone, that's not what these guidelines recommend. The guidelines aim for population-level treatment thresholds. Individual optimization is a separate conversation between you and your doctor.
They're cautious on dietary specifics
The guidelines recommend "heart-healthy dietary patterns" — Mediterranean, DASH, similar — but don't pick winners. Specific food advice (carnivore is bad, seed oils are fine, butter in moderation) is left to clinical judgment and patient preference.
They acknowledge but don't endorse new drugs
Lp(a)-lowering drugs in late-stage trials get mention, but no recommendation until they're approved and outcome data is available. Same with newer combinations.
They're conservative on diet vs. medication
Most major cardiology guidelines err on the side of medication when LDL is elevated and risk is meaningful. They don't push as hard on the lifestyle-first conversation as some preventive cardiologists would. This isn't because lifestyle doesn't work; it's because most patients don't sustain it, and guidelines have to plan for population realities.
What to do at your next appointment
If your last appointment was before March 2026, the new guidelines may shift the conversation:
- Ask for an Lp(a) test if you've never had one.
- Ask for your 10-year ASCVD risk score under the 2026 calculator (it's slightly different from the old one).
- Ask about the new LDL target for your specific risk level.
- If you're on a statin and below your old target but above the new one, ask whether to adjust.
- If you're under 40 and have elevated LDL with other risk factors, ask whether the age-30 framework applies to you.
More on what to ask at the follow-up.
Frequently asked questions
Should I aim for LDL under 70?
Depends on your 10-year cardiovascular risk. Low risk (under 5%): under 100 is generally fine. Intermediate risk (5–20%): under 70 is the new goal. High risk: under 55 increasingly recommended.
Are the new guidelines pushing more medications?
In some sense, yes — they expand the patient population eligible for statin consideration. But the framework also emphasizes lifestyle as the foundation and uses risk calculators to avoid blanket prescriptions. Most low-risk people still won't be put on medication.
What if my doctor isn't following the new guidelines yet?
Guidelines take 6–12 months to filter into routine practice. If your doctor hasn't mentioned the changes, you can. "I've read about the 2026 ACC/AHA guidelines and want to make sure we're using current targets" is a fine way to start the conversation.
Did anything get easier in the new guidelines?
A few things. Non-fasting lipid panels are now formally accepted (you don't have to fast for 8 hours unless triglycerides are very high). Coronary artery calcium scoring is more clearly endorsed for risk refinement. ApoB testing is more accessible.
Will these guidelines change again soon?
Major guideline updates happen every 5–10 years. The next big update will likely come when the Lp(a)-lowering drugs are approved (probably 2027–2028) and when more outcome data accumulates on very-low-LDL targets.
Hey Heart helps you track the dietary side of the new lower LDL targets — saturated fat, the lever that matters most. Learn more →
Hey Heart is a wellness app and not a medical device. The information in this article is general guidance only and is not medical advice, diagnosis, or treatment. Always consult your doctor about your specific health situation.